CVRX
CVRx, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$3.04
+1.33%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.99
From 52W high−71.88%
Volume632839.00
Market cap$80.99M
P/E (TTM)—
P/S (TTM)1.3x
Div yield—
Key dataSep 18, 2026
Open
$2.99
From 52W high
−71.88%
Volume
632839.00
Market cap
$80.99M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
P/E (TTM)
—
RSI (14)
40.8
MomentumView details →
1D Return
+1.33%
YTD Return
−58.66%
SummaryUpdated Jun 1, 2026
CVRx, Inc. (NASDAQ:CVRX) is a commercial-stage medical device company founded in 2000 and headquartered in Minneapolis, Minnesota. The company went public in June 2021 and specializes in developing neuromodulation solutions for cardiovascular diseases. CVRx has established itself as a pioneer in the emerging field of cardiovascular neuromodulation, focusing primarily on treating heart failure through its flagship Barostim device. After more than two decades of development and clinical testing, the company has successfully commercialized its technology and is actively expanding its market presence in the United States and Europe.
Similar companies
Latest newsMore news →
Pomerantz LLP announced an investigation into CVRx, Inc. for potential securities fraud or unlawful business practices on behalf of investors.19d agoJorey Chernett, beneficial owner of more than 5.5% of CVRx's outstanding shares, delivered a letter to the CVRx Board urging it to launch an immediate process to sell the company to a strategic acquirer.27d agoJohnson Fistel, PLLP announced an investigation into CVRx, Inc. and certain executive officers for potential violations of state or federal securities laws related to investor losses.44d ago